Table 2.
Clinical data of our patient series over the follow-up period
| Visual acuity‡ | IFA§ | IOP¶ | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Baseline | 1 month | 3 months | 6 months | 9 months | 12 months | Baseline | 1 month | 3 months | 6 months | 9 months | 12 months | Baseline | 1 month | 3 months | 6 months | 9 months | 12 months |
| 1 | CF | 6/120 | 6/60 | 6/24 | 6/18 | 6/18 | 4 | 3 | 3 | 1 | 1 | 1 | 40 | 36* | 32* | 30* | 28* | 28* |
| 1 | 6/120 | 6/60 | 6/60 | 6/24 | 6/18 | 6/18 | 3 | 3 | 2 | 1 | 1 | 1 | 28 | 25 | 22 | 22 | 24 | 22 |
| 2 | 6/60 | 6/60 | 6/24 | 6/15 | 6/15 | 6/12 | 1 | 1 | 0 | 0 | 1 | 1 | 32 | 28 | 28 | 26 | 24 | 24 |
| 3 | 6/120 | 6/120 | 6/60 | 6/24 | 6/18 | 6/24 | 2 | 1 | 1 | 0 | 0 | 0 | 30 | 26 | 24 | 24 | 22 | 22 |
| 3 | 6/60 | 6/60 | 6/30 | 6/24 | 6/18 | 6/18 | 1 | 1 | 0 | 0 | 0 | 0 | 28 | 22 | 20 | 20 | 22 | 20 |
| 4 | 6/120 | 6/120 | 6/24 | 6/15 | 6/15 | 6/18 | 1 | 0 | 0 | 1 | 0 | 1 | 36 | 24 | 24 | 22 | 24 | 22 |
| 5 | 6/120 | 6/60 | 6/60 | 6/24 | 6/36 | 6/30 | 3 | 3 | 1 | 0 | 1 | 0 | 32 | 30* | 24* | 24* | 26* | 24* |
| 6 | 6/12 | 6/12 | 6/12 | 6/15 | 6/15 | 6/18 | 2 | 1 | 2 | 0 | 0 | 0 | 30 | 26 | 26 | 26* | 24* | 24* |
| 7 | HM | 6/60 | 6/36 | 6/60 | 6/30 | 6/30 | 3 | 1 | 1 | 1 | 1 | 1 | 45 | 30 | 28* | 28* | 26* | 26* |
| 8 | 6/120 | 6/120 | 6/24 | 6/24 | 6/18 | 6/24 | 2 | 1 | 1 | 0 | 0 | 1 | 25 | 19 | 20 | 20 | 22 | 22 |
| 9 | HM | 6/120 | 6/120 | 6/30 | 6/36 | 6/30 | 4 | 2 | 2 | 1 | 1 | 1 | 35 | 30* | 30* | 30* | 26* | 26* |
| 10 | 6/24 | 6/24 | 6/24 | 6/15 | 6/15 | 6/24 | 2 | 1 | 0 | 0 | 0 | 0 | 30 | 18 | 18 | 18 | 20 | 18 |
| 11 | CF | CF | CF | 6/60 | 6/30 | 6/36 | 4 | 3 | 3 | 1 | 0 | 0 | 50 | 38* | 32* | 22* | 20 | 20* |
| 12 | HM | CF | 6/60 | 6/60 | 6/30 | 6/36 | 4 | 2 | 2 | 1 | 1 | 1 | 45 | 18* | 20* | 20* | 22 | 20* |
| 12 | 6/60 | 6/24 | 6/24 | 6/24 | 6/18 | 6/24 | 2 | 1 | 0 | 0 | 0 | 0 | 30 | 18* | 18* | 18* | 20 | 20* |
| 13 | 6/60 | 6/60 | 6/18 | 6/18 | 6/18 | 6/18 | 3 | 1 | 2 | 1 | 0 | 0 | 51 | 45 | 30† | 21 | 22 | 21 |
| 14 | 6/15 | 6/12 | 6/15 | 6/12 | 6/15 | 6/18 | 2 | 2 | 0 | 0 | 1 | 1 | 18 | 16 | 19 | 18 | 20 | 18 |
| 15 | 6/60 | 6/36 | 6/24 | 6/24 | 6/18 | 6/18 | 3 | 3 | 1 | 0 | 0 | 0 | 50 | 32* | 20* | 22* | 20* | 20* |
| 16 | 6/120 | 6/60 | 6/60 | 6/30 | 6/36 | 6/30 | 2 | 1 | 1 | 1 | 1 | 1 | 50 | 41† | 18 | 20 | 22 | 22 |
| 17 | HM | 6/36 | 6/36 | 6/36 | 6/30 | 6/30 | 3 | 2 | 1 | 2 | 2 | 2 | 44 | 40* | 36* | 32* | 28* | 28* |
| 18 | 6/60 | 6/24 | 6/24 | 6/36 | 6/30 | 6/36 | 3 | 1 | 0 | 0 | 0 | 0 | 32 | 32 | 28* | 30* | 28* | 30* |
| 19 | 6/120 | 6/36 | 6/60 | 6/60 | 6/30 | 6/36 | 4 | 2 | 1 | 1 | 1 | 0 | 30 | 24* | 24* | 22* | 24* | 22* |
| 20 | HM | 6/36 | CF | 6/36 | 6/30 | 6/30 | 3 | 3 | 2 | 0 | 0 | 1 | 32 | 22* | 24* | 22* | 22* | 22* |
| 21 | HM | CF | 6/60 | 6/36 | 6/36 | 6/36 | 3 | 2 | 1 | 0 | 0 | 1 | 42 | 33† | 24 | 22 | 22 | 22 |
| 22 | 6/120 | 6/36 | 6/60 | 6/24 | 6/24 | 6/30 | 4 | 2 | 1 | 1 | 1 | 0 | 38 | 28* | 30* | 28* | 24* | 26* |
| 23 | CF | 6/60 | 6/36 | 6/24 | 6/18 | 6/24 | 4 | 2 | 2 | 1 | 1 | 1 | 34 | 28* | 32* | 28* | 26* | 28* |
*
On treatment with topical IOP-lowering drops.
†
Ahmed glaucoma valve implant.
‡
Paired t-test (baseline vs. 12 months; t = −7.912, P = 0.0001; 95% CI −0.22, −0.13).
§
Spearman's rank correlation (P < 0.01).
¶
Paired t-test (baseline vs. 12 months; t = 7.867, P = 0.0001; 95% CI 9.91, 16.94). CRVO, central retinal vein occlusion; IFA, iris fluorescein angiography (graded according to the Ehrenberg's system); IOP, intraocular pressure; PDR, proliferative diabetic retinopathy.